Flashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term Safety
Authors: Gary K. Schwartz
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. February 07, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02333 Journal of Clinical Oncology - published online before print February 7, 2023 PMID: 36750015 Flashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term Safety Gary K. Schwartz, MD1,2xGary K. SchwartzSearch for articles by this author Show More 1Columbia University, New York, NY2Associate Editor, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02333 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2014, Topalian et al1 published the first study to show that a programmed cell death protein 1 checkpoint inhibitor (nivolumab) could safely prolong survival in patients with metastatic melanoma. It became the benchmark for the evolution of the treatment in this disease that was to follow.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term SafetyThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Gary K. SchwartzThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Stock and Other Ownership Interests: GenCirq, Bionaut Labs, January TherapeuticsConsulting or Advisory Role: Bionaut Labs, Ellipses Pharma, Gencirq, Epizyme, Array BioPharma, Apexigen, Oncogenuity, OnCusp Therapeutics, Concarlo, Shanghai Pharma, Astex Pharmaceuticals, January Therapeutics, Sellas Life Sciences, PureTech, AADi, Kirilys TherapeuticsResearch Funding: Astex Pharmaceuticals, Incyte (Inst), Calithera Biosciences (Inst), Lilly (Inst), Daiichi Sankyo (Inst), Fortress Biotech (Inst), Karyopharm Therapeutics (Inst), Oxford BioTherapeutics (Inst), Astex Pharmaceuticals (Inst), TopAlliance BioSciences Inc (Inst), Adaptimmune (Inst), SpringWorks Therapeutics (Inst), TRACON Pharma (Inst)Patents, Royalties, Other Intellectual Property: Companion diagnostics for CD4 inhibitors (Inst), patent granted to develop a new technology called PNAs for cancer therapyTravel, Accommodations, Expenses: Array BioPharmaNo other potential conflicts of interest were reported. Companion Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab